Esperion Therapeutics, Inc.
ESPRDelisted Jul 13, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001434868
Esperion Therapeutics, Inc. was delisted on Jul 13, 2026; its insiders filed their last Form 4 on Jul 13, 2026; 191 institutions reported holding it in 13F filings for Q2 2026, worth $646.8M in total; Soros Fund Management was the only superinvestor holding it.
Q4 2024 vs. Q3 2024
How the institutions holding Esperion Therapeutics, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Of which not filed for Q4 2024 | Q4 2024 | Change |
|---|---|---|---|---|
| Holders | 184 | 2 | 190 | +8 |
| Shares | 129.5M | 3.84M | 126.3M | +619.0K (+0.5%) |
| Value | $214.3M | $6.34M | $277.9M | +$69.9M (+33.6%) |
2 institutions that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (34)
Institutions that held Esperion Therapeutics, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
Sold out (26)
Institutions that held Esperion Therapeutics, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
Not filed for Q4 2024 yet (2)
Institutions that held Esperion Therapeutics, Inc. at the end of Q3 2024 and haven't filed a 13F for Q4 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Meditor Group Ltd | 3,791,300 | $6.26M |
| Raymond James & Associates | 50,657 | $83.6K |